JP5138844B2 - 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強 - Google Patents

抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強 Download PDF

Info

Publication number
JP5138844B2
JP5138844B2 JP2000553593A JP2000553593A JP5138844B2 JP 5138844 B2 JP5138844 B2 JP 5138844B2 JP 2000553593 A JP2000553593 A JP 2000553593A JP 2000553593 A JP2000553593 A JP 2000553593A JP 5138844 B2 JP5138844 B2 JP 5138844B2
Authority
JP
Japan
Prior art keywords
sequence
ebv
use according
seq
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000553593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002517249A (ja
JP2002517249A5 (cg-RX-API-DMAC7.html
Inventor
モンド,ジェームズ,ジェイ.
リーズ,アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002517249A publication Critical patent/JP2002517249A/ja
Publication of JP2002517249A5 publication Critical patent/JP2002517249A5/ja
Application granted granted Critical
Publication of JP5138844B2 publication Critical patent/JP5138844B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000553593A 1998-06-12 1999-06-10 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強 Expired - Fee Related JP5138844B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8915898P 1998-06-12 1998-06-12
US60/089,158 1998-06-12
PCT/US1999/013113 WO1999064603A2 (en) 1998-06-12 1999-06-10 ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012116568A Division JP2012214477A (ja) 1998-06-12 2012-05-22 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強

Publications (3)

Publication Number Publication Date
JP2002517249A JP2002517249A (ja) 2002-06-18
JP2002517249A5 JP2002517249A5 (cg-RX-API-DMAC7.html) 2006-07-13
JP5138844B2 true JP5138844B2 (ja) 2013-02-06

Family

ID=22216014

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000553593A Expired - Fee Related JP5138844B2 (ja) 1998-06-12 1999-06-10 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強
JP2012116568A Pending JP2012214477A (ja) 1998-06-12 2012-05-22 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012116568A Pending JP2012214477A (ja) 1998-06-12 2012-05-22 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強

Country Status (6)

Country Link
US (1) US6432679B1 (cg-RX-API-DMAC7.html)
EP (1) EP1086231A2 (cg-RX-API-DMAC7.html)
JP (2) JP5138844B2 (cg-RX-API-DMAC7.html)
AU (1) AU762799B2 (cg-RX-API-DMAC7.html)
CA (1) CA2331258C (cg-RX-API-DMAC7.html)
WO (1) WO1999064603A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012214477A (ja) * 1998-06-12 2012-11-08 Henry M Jackson Foundation For The Advancement Of Military Medicine Inc 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
FR2819724B1 (fr) * 2001-01-22 2005-05-13 Inst Necker Moyens pour induire une reponse immune aux antigenes bacteriens polysccharidiques et aux structures proteiques des capsides de virus
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
EP1539811A4 (en) * 2002-09-16 2006-05-24 Elusys Therapeutics Inc PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
EP1599170B1 (en) * 2003-02-21 2013-01-16 Hasumi Llc (Dba Shukokai International) Human lymphocyte vaccine adjuvant
CA2556169C (en) * 2004-01-29 2011-11-22 Andrew Lees Use of amino-oxy functional groups in the preparation of vaccines
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
JP5250548B2 (ja) * 2006-06-21 2013-07-31 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 疾患の治療のための補体h因子の標的化
AU2010268367B2 (en) 2009-07-02 2016-10-20 Ith Immune Therapy Holdings Ab Exosome based treatment of cancer
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
WO2011017101A2 (en) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
BR122022002139B1 (pt) 2009-12-17 2022-08-23 Fina Biosolutions, Llc Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas
ES2743156T3 (es) 2010-04-23 2020-02-18 Serum Institute Of India Pvt Ltd Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
MX2012013233A (es) 2010-05-14 2013-05-20 Univ Colorado Regents Grupos que apuntan a receptor 2 de complemento (cr2) mejorados.
BR112012033119A2 (pt) 2010-06-22 2016-10-25 Univ Colorado Regents anticorpos para o fragamento c3d do componente do complemento 3.
EP2877205A4 (en) * 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
AU4341189A (en) * 1988-10-03 1990-05-01 Scripps Clinic And Research Foundation The receptor binding region of ebvgp350
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5310729A (en) 1990-04-20 1994-05-10 California Institute Of Biological Research Interferon-related polypeptides as CR2 ligands and their use for modulating immune cell functions
US5331090A (en) 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
EP0625910B1 (en) 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
US5521066A (en) 1993-09-13 1996-05-28 Bristol-Myers Squibb Company Periplasmic membrane-bound system for detecting protein-protein interactions
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
GB9424631D0 (en) 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
DE69628418T2 (de) * 1995-03-22 2004-04-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
AU762799B2 (en) * 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012214477A (ja) * 1998-06-12 2012-11-08 Henry M Jackson Foundation For The Advancement Of Military Medicine Inc 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強

Also Published As

Publication number Publication date
EP1086231A2 (en) 2001-03-28
US6432679B1 (en) 2002-08-13
JP2012214477A (ja) 2012-11-08
WO1999064603A2 (en) 1999-12-16
JP2002517249A (ja) 2002-06-18
AU762799B2 (en) 2003-07-03
AU4559499A (en) 1999-12-30
WO1999064603A3 (en) 2000-02-10
CA2331258A1 (en) 1999-12-16
CA2331258C (en) 2011-09-20
US20020119529A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
JP2012214477A (ja) 抗原およびEBVGp350/220の受容体の同時刺激によるB細胞活性化および免疫グロブリン分泌の増強
KR100290632B1 (ko) 면역성이약한항원공액체와이를포함하는합성펩티드담체와백신
JP4713809B2 (ja) B型肝炎コア抗原融合タンパク質
ES2144424T5 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
JP7555598B2 (ja) 合成ペプチド免疫原のための免疫刺激薬としての人工無差別tヘルパー細胞エピトープ
JP4031201B2 (ja) アレルギー治療用免疫原としてのペプチド組成物
Cui et al. A novel tetrameric gp3501–470 as a potential Epstein–Barr virus vaccine
JP2018138581A (ja) 多量体融合タンパク質ワクチン及び免疫療法
CN106102769A (zh) 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途
US9937252B2 (en) Induction of cross-reactive cellular response against rhinovirus antigens
KR20110088526A (ko) 구제역 백신 조성물 및 이의 제조 방법
RU2454462C2 (ru) Частицы с расщепленным ядром, предназначенные для презентации чужеродных молекул, прежде всего для применения в вакцинах, и способ их получения
Dalum et al. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope
JP2022513452A (ja) 融合によって修飾されたcmvのウイルス様粒子
KR20230084478A (ko) 면역원성 코로나 바이러스 융합 단백질 및 관련 방법
JPH07505365A (ja) 耐性の誘導に有用なペプチド
US20070053920A1 (en) Nematode polypeptide adjuvant
CN105777909B (zh) 一种猪趋化因子介导的a型口蹄疫靶向性复合表位蛋白及疫苗
WO2022083805A1 (es) Antígeno quimérico que comprende el dominio extracelular de pd-l1
WO2022242432A1 (en) Peptide vaccine for virus infection
MXPA02006313A (es) Vacunacion de acido nucleico.
Astori et al. Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic
WO2022106860A1 (en) Recombinant peptides for use in therapy
He et al. Immunogenic comparison for two different recombinant chimeric peptides (CP12 and CP22) containing one or two copies of three linear B cell epitopes from β-hCG subunit
RU2839585C2 (ru) Искусственные неизбирательные эпитопы клеток т-хелперов как иммунные стимуляторы для синтетических пептидных иммуногенов

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121016

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121115

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees